Evidence map›Paper›PMID 27574175›Full record

ReviewThe British journal of ophthalmology2017

Metastatic disease from uveal melanoma: treatment options and future prospects.

Richard D Carvajal, Gary K Schwartz, Tongalp Tezel, Brian Marr, Jasmine H Francis, Paul D Nathan

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The British journal of ophthalmology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 252 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
252citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

252 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. The multiple roles of autophagy in uveal melanoma and the microenvironment.Journal of cancer research and clinical oncology · 2024
    Pooled it
  6. Guideline
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Topotecan Synergizes with SP141 in the Management of Uveal Melanoma.bioRxiv : the preprint server for biology · 2026
    Article
  16. Review
  17. Article
  18. Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
  19. Article
  20. Article

192 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Richard D CarvajalDivision of Hematology/Oncology, Columbia University Medical Center, New York, USA.
Gary K SchwartzDivision of Hematology/Oncology, Columbia University Medical Center, New York, USA.
Tongalp TezelDepartment of Ophthalmology, Columbia University Medical Center, New York, USA.
Brian MarrDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA.
Jasmine H FrancisDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA.
Paul D NathanDivision of Cancer Services, Mt Vernon Cancer Centre, Northwood, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Uveal melanoma represents ∼85% of all ocular melanomas and up to 50% of patients develop metastatic disease. Metastases are most frequently localised to the liver and, as few patients are candidates for potentially curative surgery, this is associated with a poor prognosis. There is currently little published evidence for the optimal management and treatment of metastatic uveal melanoma and the lack of effective therapies in this setting has led to the widespread use of systemic treatments for patients with cutaneous melanoma. Uveal and cutaneous melanomas are intrinsically different diseases and so dedicated management strategies and therapies for uveal melanoma are much needed. This review explores the biology of uveal melanoma and how this relates to ongoing trials of targeted therapies in the metastatic disease setting. In addition, we consider the options to optimise patient management and care.

Indexed as

HumansIncidenceLiver NeoplasmsMelanomaMolecular BiologyMolecular Targeted TherapyNeoplasm MetastasisPrognosisUveal MelanomaUveal NeoplasmsChoroidCiliary bodyDrugsIrisTreatment Medical

Identifiers

PMID27574175
PMCPMC5256122

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.